<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01593020</url>
  </required_header>
  <id_info>
    <org_study_id>2012-0167</org_study_id>
    <secondary_id>NCI-2012-00851</secondary_id>
    <nct_id>NCT01593020</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2</brief_title>
  <official_title>A Randomized Phase II Neoadjuvant Study of Sequential Eribulin Followed by FAC/FEC-regimen Compared to Sequential Paclitaxel Followed by FAC/FEC-Regimen in Women With Early Stage Breast Cancer Not Overexpressing HER-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if and how well eribulin, given in&#xD;
      combination with standard chemotherapy, can treat early-stage breast cancer compared to&#xD;
      paclitaxel given in combination with standard chemotherapy. In this study, the standard&#xD;
      chemotherapy being given is either 5-fluorouracil, epirubicin, and cyclophosphamide (called&#xD;
      FEC) or 5-fluorouracil, doxorubicin, and cyclophosphamide (called FAC).&#xD;
&#xD;
      Eribulin is a changed version of the structure of a natural substance from a sea sponge. It&#xD;
      is designed to block cells from dividing, which may cause cancer cells to die.&#xD;
&#xD;
      Paclitaxel is designed to block cancer cells from dividing, which may cause them to die.&#xD;
&#xD;
      5-fluorouracil is designed to block cancer cells from growing and dividing, which may slow or&#xD;
      stop their growth and spread throughout the body. This may cause the cancer cells to die.&#xD;
&#xD;
      Epirubicin is designed to block the way cancer cells grow and divide, which may slow or stop&#xD;
      their growth and spread throughout the body. This may cause the cancer cells to die.&#xD;
&#xD;
      Doxorubicin is designed to stop the growth of cancer cells, which may cause the cells to die.&#xD;
&#xD;
      Cyclophosphamide is designed to interfere with the multiplication of cancer cells, which may&#xD;
      slow or stop their growth and/or keep them from spreading throughout the body. This may cause&#xD;
      the cancer cells to die.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Groups If you are found to be eligible to take part in this study, you will be randomly&#xD;
      assigned (as in the flip of a coin) to 1 of 2 groups. You will have an equal chance of being&#xD;
      assigned to either group.&#xD;
&#xD;
      If you are in Group 1, you will receive paclitaxel for 4 cycles. You also will be treated&#xD;
      with FAC or FEC for 4 cycles. Your treating doctor will decide whether you will receive FEC&#xD;
      or FAC.&#xD;
&#xD;
      If you are in Group 2, you will receive eribulin for 4 cycles. You will also be treated with&#xD;
      FAC or FEC for 4 cycles. Your treating doctor will decide whether you will receive FEC or&#xD;
      FAC.&#xD;
&#xD;
      Each cycle is 21 days.&#xD;
&#xD;
      Study Drug Administration for Group 1 You will receive paclitaxel by vein over 1 hour on Days&#xD;
      1, 8, and 15 of each 21-day study cycle.&#xD;
&#xD;
      Before the infusion, you will be given drugs by vein, to help decrease the risk of an&#xD;
      allergic reaction.&#xD;
&#xD;
      If you have severe side effects, future treatments may be delayed, the dose may be decreased,&#xD;
      or you may be taken off study.&#xD;
&#xD;
      Once you have received 4 cycles of paclitaxel, you will receive either FEC or FAC&#xD;
      chemotherapy for 4 cycles. Your treating doctor will decide whether you will receive FEC or&#xD;
      FAC.&#xD;
&#xD;
      Study Drug Administration for Group 2 You will receive eribulin by vein over 2-5 minutes on&#xD;
      Days 1 and 8 of each 21-day study cycle.&#xD;
&#xD;
      Once you have received 4 cycles of eribulin, you will receive FEC or FAC chemotherapy for 4&#xD;
      cycles. Your treating doctor will decide whether you will receive FEC or FAC.&#xD;
&#xD;
      FEC or FAC Treatment After you have received 4 cycles of either paclitaxel or eribulin, you&#xD;
      will receive FEC or FAC.&#xD;
&#xD;
      If you are given FEC chemotherapy, you will receive 5-Fluorouracil by vein over 15 minutes,&#xD;
      epirubicin by vein over 30 minutes, and cyclophosphamide by vein over 30-60 minutes on Day 1&#xD;
      of every 21-day cycle.&#xD;
&#xD;
      If you are given FAC chemotherapy, you will receive 5-Fluorouracil by vein over 15 minutes,&#xD;
      doxorubicin by vein over 15 minutes, and cyclophosphamide by vein over 30-60 minutes on Day 1&#xD;
      of 21-day cycle.&#xD;
&#xD;
      Before FEC or FAC chemotherapy, you will be given drugs by vein to help decrease the risk of&#xD;
      allergic reaction. These drugs will include dexamethasone and zofran.&#xD;
&#xD;
      Study Visits During Paclitaxel or Eribulin On Day 1 of each cycle: If you have had these&#xD;
      tests within 10 days before Day 1 of Cycle 1, they may not need to be repeated.&#xD;
&#xD;
      You will have a physical exam, including a measurement of your weight and vital signs.&#xD;
&#xD;
      You will be asked about any side effects you may be having and any drugs you may be taking.&#xD;
&#xD;
      Your performance status will be recorded. Blood (about 1-2 teaspoons) will be drawn for&#xD;
      routine tests.&#xD;
&#xD;
      On Days 8 and 15 of Cycle 1-4, blood (about 1 teaspoon) will be drawn for routine tests.&#xD;
&#xD;
      At Week 12, you will have a core biopsy.&#xD;
&#xD;
      At the end of Cycle 4:&#xD;
&#xD;
      You will have an ultrasound of the breast to check the status of the disease. You will have&#xD;
      an ECHO or MUGA scan. You will have a core biopsy and fine needle aspiration of the tumor. A&#xD;
      small needle will be inserted into the tumor at the safest and easiest location to withdraw&#xD;
      cancer cells. This will be used to learn which tumor markers may predict who may best respond&#xD;
      to therapy.&#xD;
&#xD;
      Study Visits During FEC or FAC Chemotherapy&#xD;
&#xD;
      On Day 1 of every third week:&#xD;
&#xD;
      You will have a physical exam, including a measurement of your weight and vital signs.&#xD;
&#xD;
      You will be asked about any side effects you may be having and any drugs you may be taking.&#xD;
&#xD;
      Your performance status will be recorded. Blood (about 1-2 teaspoons) will be drawn for&#xD;
      routine tests.&#xD;
&#xD;
      After you have finished FEC or FAC treatment, you may have surgery. At the end of the&#xD;
      chemotherapy treatment, you will be referred to the breast surgeon to discuss surgery. There&#xD;
      is an small possibility (less than 3%) that tumor has gotten worse during treatment, and&#xD;
      additional chemotherapy may be necessary.&#xD;
&#xD;
      Length of Study You may continue taking the study drug for as long as the doctor thinks it is&#xD;
      in your best interest. You will no longer be able to take the study drug if the disease gets&#xD;
      worse, if intolerable side effects occur, or if you are unable to follow study directions.&#xD;
&#xD;
      This is an investigational study. Paclitaxel, doxorubicin, epirubicin, and cyclophosphamide&#xD;
      are FDA approved and commercially available for the treatment of breast cancer. Eribulin is&#xD;
      FDA approved and commercially available to treat metastatic breast cancer in patients who&#xD;
      have received at least 2 chemotherapy regimens for the treatment of metastatic disease. The&#xD;
      use of eribulin with the FEC/FAC regimens is investigational for neoadjuvant treatment.&#xD;
&#xD;
      Eribulin will be provided at no cost to you while you are on this study. You and/or your&#xD;
      insurance provider will be responsible for the cost of paclitaxel, doxorubicin, epirubicin,&#xD;
      and cyclophosphamide.&#xD;
&#xD;
      Up to 162 patients will take part in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 3, 2012</start_date>
  <completion_date type="Actual">November 4, 2020</completion_date>
  <primary_completion_date type="Actual">November 4, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response (pCR)</measure>
    <time_frame>4 -6 weeks from last dose of FAC/FEC-regimen.</time_frame>
    <description>Pathologic complete response (pCR) defined as complete absence of any viable invasive cancer cells in the resected breast and lymph nodes. Participants undergo definitive breast surgery 4 -6 weeks from last dose of FAC/FEC-regimen. Tumors removed by either lumpectomy with axillary dissection (i.e. breast conservation surgery) or modified radical mastectomy (i.e. mastectomy with axillary clearance). Surgical specimens (breast and axillary lymph node tissue) evaluated for pathological complete response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>5 Year Event Free Survival (EFS)</measure>
    <time_frame>from start of treatment, up to 5 years</time_frame>
    <description>Event free survival (EFS) the length of time after primary treatment for a cancer ends that the patient remains free of certain complications or events that the treatment was intended to prevent or delay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>from start of treatment, up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Paclitaxel + FEC or FAC Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARM 1: Participants receive Paclitaxel 80 mg/m2 by vein over 1 hour weekly for 12 doses of a 21 day cycle.&#xD;
Participants on both arms receive FEC or FAC for 4 cycles (21 day cycle) at the preference of the treating physicians.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eribulin + FEC or FAC Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARM 2: Participants receive Eribulin 1.4 mg/m2 by vein over 2-5 minutes on days 1 and 8 every 3 weeks for 4 cycles (21 day cycle).&#xD;
Participants on both arms receive FEC or FAC for 4 cycles (21 day cycle) at the preference of the treating physicians.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>80 mg/m2 by vein over 1 hour on Days 1, 8, and 15 of each 21-day cycle.</description>
    <arm_group_label>Paclitaxel + FEC or FAC Group</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eribulin</intervention_name>
    <description>1.4 mg/m2 by vein over 2-5 minutes on Days 1 and 8 of each 21-day study cycle.</description>
    <arm_group_label>Eribulin + FEC or FAC Group</arm_group_label>
    <other_name>E7389</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.</description>
    <arm_group_label>Eribulin + FEC or FAC Group</arm_group_label>
    <arm_group_label>Paclitaxel + FEC or FAC Group</arm_group_label>
    <other_name>5-FU</other_name>
    <other_name>Adrucil</other_name>
    <other_name>Efudex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>100 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.</description>
    <arm_group_label>Eribulin + FEC or FAC Group</arm_group_label>
    <arm_group_label>Paclitaxel + FEC or FAC Group</arm_group_label>
    <other_name>Ellence</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.</description>
    <arm_group_label>Eribulin + FEC or FAC Group</arm_group_label>
    <arm_group_label>Paclitaxel + FEC or FAC Group</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>50 mg/m2 by vein on day 1, over 72 hour continuous infusion or intravenous bolus, for 4 cycles (21 day cycle) at preference of treating physicians.</description>
    <arm_group_label>Eribulin + FEC or FAC Group</arm_group_label>
    <arm_group_label>Paclitaxel + FEC or FAC Group</arm_group_label>
    <other_name>Doxorubicin Hydrochloride</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent&#xD;
&#xD;
          2. Histologically confirmed primary invasive adenocarcinoma of the breast.&#xD;
&#xD;
          3. Clinical stage breast cancer T2-3, N0-3, M0&#xD;
&#xD;
          4. Negative HER-2/neu expression as determined by local hospital laboratory using&#xD;
             Fluorescence In Situ Hybridization (FISH), or is less or equal to 1+ using&#xD;
             Immunohistochemistry (IHC).&#xD;
&#xD;
          5. No prior treatment for primary invasive adenocarcinoma of the breast such as&#xD;
             irradiation, chemotherapy, hormonal therapy, immunotherapy, investigational therapy or&#xD;
             surgery. Subjects receiving hormone replacement treatment (HRT) are eligible if this&#xD;
             therapy is discontinued at least 2 weeks before starting study treatment. Treatment&#xD;
             for DCIS is allowed, such as surgery, hormonal therapy and radiotherapy.&#xD;
&#xD;
          6. Karnofsky performance status (KPS) of 80 - 100&#xD;
&#xD;
          7. The ability and willingness to comply with scheduled visits, treatment plan,&#xD;
             laboratory tests, and other study procedures.&#xD;
&#xD;
          8. Baseline MUGA or echocardiogram scans with LVEF of &gt; 50%.&#xD;
&#xD;
          9. Normal PTT and either INR or PT &lt; 1.5 x ULN.&#xD;
&#xD;
         10. Men or women 18 years of age or older.&#xD;
&#xD;
         11. Women of childbearing potential (WOCBP) must agree to use a medically acceptable&#xD;
             method of contraception to avoid pregnancy throughout the study and for up to 8 weeks&#xD;
             after the last dose of study drugs.&#xD;
&#xD;
         12. Willingness to have core biopsies and/or FNA performed before the start of study&#xD;
             treatment and at the end of 12 week on treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant (including positive pregnancy test at enrollment or prior to&#xD;
             study drug administration) or breast-feeding.&#xD;
&#xD;
          2. Disease free of prior malignancy for &lt; 5 years with the exception of DCIS, curatively&#xD;
             treated basal carcinoma of the skin, local skin squamous cell carcinoma, or carcinoma&#xD;
             in situ of the cervix.&#xD;
&#xD;
          3. Absolute neutrophils count (ANC) &lt; 1500/mm^3&#xD;
&#xD;
          4. Total bilirubin &gt; 1.5 times the upper limit of normal (ULN)&#xD;
&#xD;
          5. AST or ALT &gt; 2.5 times the upper limit of normal (ULN)&#xD;
&#xD;
          6. Platelets &lt; 100,000/mm^3.&#xD;
&#xD;
          7. Serum creatinine &gt; 1.5 x ULN or creatinine clearance &lt; 60 mL/min (measured or&#xD;
             calculated by Cockcroft-Galt method)&#xD;
&#xD;
          8. Evidence of metastatic breast cancer following a standard tumor staging work-up&#xD;
&#xD;
          9. Evidence of inflammatory breast cancer.&#xD;
&#xD;
         10. Evidence of any grade 2 sensory or motor neuropathy.&#xD;
&#xD;
         11. Known human immunodeficiency viral (HIV) infection&#xD;
&#xD;
         12. Serious intercurrent infections or non-malignant medical illness that are uncontrolled&#xD;
             or the control of which may be jeopardized by this therapy.&#xD;
&#xD;
         13. Psychiatric disorders or other conditions rendering the subject incapable of complying&#xD;
             with the requirements of the protocols.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vicente Valero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 3, 2012</study_first_submitted>
  <study_first_submitted_qc>May 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2012</study_first_posted>
  <results_first_submitted>August 26, 2021</results_first_submitted>
  <results_first_submitted_qc>August 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 22, 2021</results_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Early Stage Breast Cancer Not Overexpressing HER-2</keyword>
  <keyword>Primary invasive adenocarcinoma of the breast</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Taxol</keyword>
  <keyword>Eribulin</keyword>
  <keyword>E7389</keyword>
  <keyword>5-Fluorouracil</keyword>
  <keyword>5-FU</keyword>
  <keyword>Adrucil</keyword>
  <keyword>Efudex</keyword>
  <keyword>Epirubicin</keyword>
  <keyword>Ellence</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Cytoxan</keyword>
  <keyword>Neosar</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Doxorubicin hydrochloride</keyword>
  <keyword>Adriamycin PFS</keyword>
  <keyword>Adriamycin RDF</keyword>
  <keyword>Adriamycin</keyword>
  <keyword>Rubex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 22, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT01593020/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from August 2012 to July 2014. This study was conducted at the University of Texas MD Anderson Cancer Center main campus and the Regional Care Centers (RCC).</recruitment_details>
      <pre_assignment_details>54 patients were accrued. 28 patients were randomized to Paclitaxel and 26 patients to Eribulin group. 2 patients from eribulin were found ineligible and never received treatment and 1 patient withdrew due to physician decision.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Paclitaxel Weekly for 12 Doses Followed by FAC/FEC</title>
          <description>Patients will receive Paclitaxel 80 mg/m2 IVPB over 1 hour weekly for 12 doses followed by FAC/FEC.</description>
        </group>
        <group group_id="P2">
          <title>Eribulin on Days 1 and 8 Every 3 Weeks for 4 Cycles (21 Day Cycle) Followed by FAC/FEC</title>
          <description>Patients will receive eribulin 1.4 mg/m2 IV infusion or per institutional guidelines over 2-5 minutes on days 1 and 8 every 3 weeks for 4 cycles (21 day cycle) followed by FAC/FEC.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Paclitaxel Weekly for 12 Doses Followed by FAC/FEC</title>
          <description>Patients will receive Paclitaxel 80 mg/m2 IVPB over 1 hour weekly for 12 doses followed by FAC/FEC.</description>
        </group>
        <group group_id="B2">
          <title>Eribulin on Days 1 and 8 Every 3 Weeks for 4 Cycles (21 Day Cycle) Followed by FAC/FEC</title>
          <description>Patients will receive eribulin 1.4 mg/m2 IV infusion or per institutional guidelines over 2-5 minutes on days 1 and 8 every 3 weeks for 4 cycles (21 day cycle) followed by FAC/FEC.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathologic Complete Response (pCR)</title>
        <description>Pathologic complete response (pCR) defined as complete absence of any viable invasive cancer cells in the resected breast and lymph nodes. Participants undergo definitive breast surgery 4 -6 weeks from last dose of FAC/FEC-regimen. Tumors removed by either lumpectomy with axillary dissection (i.e. breast conservation surgery) or modified radical mastectomy (i.e. mastectomy with axillary clearance). Surgical specimens (breast and axillary lymph node tissue) evaluated for pathological complete response.</description>
        <time_frame>4 -6 weeks from last dose of FAC/FEC-regimen.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paclitaxel Weekly for 12 Doses Followed by FAC/FEC</title>
            <description>Patients will receive Paclitaxel 80 mg/m2 IVPB over 1 hour weekly for 12 doses followed by FAC/FEC.</description>
          </group>
          <group group_id="O2">
            <title>Eribulin on Days 1 and 8 Every 3 Weeks for 4 Cycles (21 Day Cycle) Followed by FAC/FEC</title>
            <description>Patients will receive eribulin 1.4 mg/m2 IV infusion or per institutional guidelines over 2-5 minutes on days 1 and 8 every 3 weeks for 4 cycles (21 day cycle) followed by FAC/FEC.</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Complete Response (pCR)</title>
          <description>Pathologic complete response (pCR) defined as complete absence of any viable invasive cancer cells in the resected breast and lymph nodes. Participants undergo definitive breast surgery 4 -6 weeks from last dose of FAC/FEC-regimen. Tumors removed by either lumpectomy with axillary dissection (i.e. breast conservation surgery) or modified radical mastectomy (i.e. mastectomy with axillary clearance). Surgical specimens (breast and axillary lymph node tissue) evaluated for pathological complete response.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5 Year Event Free Survival (EFS)</title>
        <description>Event free survival (EFS) the length of time after primary treatment for a cancer ends that the patient remains free of certain complications or events that the treatment was intended to prevent or delay.</description>
        <time_frame>from start of treatment, up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paclitaxel Weekly for 12 Doses Followed by FAC/FEC</title>
            <description>Patients will receive Paclitaxel 80 mg/m2 IVPB over 1 hour weekly for 12 doses followed by FAC/FEC.</description>
          </group>
          <group group_id="O2">
            <title>Eribulin on Days 1 and 8 Every 3 Weeks for 4 Cycles (21 Day Cycle) Followed by FAC/FEC</title>
            <description>Patients will receive eribulin 1.4 mg/m2 IV infusion or per institutional guidelines over 2-5 minutes on days 1 and 8 every 3 weeks for 4 cycles (21 day cycle) followed by FAC/FEC.</description>
          </group>
        </group_list>
        <measure>
          <title>5 Year Event Free Survival (EFS)</title>
          <description>Event free survival (EFS) the length of time after primary treatment for a cancer ends that the patient remains free of certain complications or events that the treatment was intended to prevent or delay.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <time_frame>from start of treatment, up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paclitaxel Weekly for 12 Doses Followed by FAC/FEC</title>
            <description>Patients will receive Paclitaxel 80 mg/m2 IVPB over 1 hour weekly for 12 doses followed by FAC/FEC.</description>
          </group>
          <group group_id="O2">
            <title>Eribulin on Days 1 and 8 Every 3 Weeks for 4 Cycles (21 Day Cycle) Followed by FAC/FEC</title>
            <description>Patients will receive eribulin 1.4 mg/m2 IV infusion or per institutional guidelines over 2-5 minutes on days 1 and 8 every 3 weeks for 4 cycles (21 day cycle) followed by FAC/FEC.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="84.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The duration of chemotherapy treatment per subject will be approximately 6 months, corresponding to 4 cycles of eribulin followed by 4 cycles of FAC/FEC-regimen or 12 cycles of weekly paclitaxel followed by 4 cycles of FAC/FEC-regimen. Post chemotherapy, patient will undergo definitive breast surgery 4 -6 weeks from last dose of FAC/FEC-regimen. 2 weeks Follow up post surgery</time_frame>
      <desc>Only &gt;/= grade 3 serious adverse events are reported</desc>
      <group_list>
        <group group_id="E1">
          <title>Paclitaxel Weekly for 12 Doses Followed by FAC/FEC</title>
          <description>Patients will receive Paclitaxel 80 mg/m2 IVPB over 1 hour weekly for 12 doses followed by FAC/FEC.</description>
        </group>
        <group group_id="E2">
          <title>Eribulin on Days 1 and 8 Every 3 Weeks for 4 Cycles (21 Day Cycle) Followed by FAC/FEC</title>
          <description>Patients will receive eribulin 1.4 mg/m2 IV infusion or per institutional guidelines over 2-5 minutes on days 1 and 8 every 3 weeks for 4 cycles (21 day cycle) followed by FAC/FEC.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Valero Vicente, Professor, Breast Medical Oncology</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>(713) 563-0751</phone>
      <email>vvalero@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

